Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis

Vaccine

Volumn 31, Issue 46, 2013, Pages 5349-5358

  Ruiz Aragon J ^a   Peláez, S Márquez ^b   Molina Linde, J M ^b   Grande Tejada, A M ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^c HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Immunogenicity; Meta analysis; Pneumococcal conjugate vaccine; Safety

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; DECREASED APPETITE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; META ANALYSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP; SYSTEMATIC REVIEW; VACCINATION;

IMMUNOGENICITY; META-ANALYSIS; PNEUMOCOCCAL CONJUGATE VACCINE; SAFETY;

ANTIBODIES, BACTERIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886092970     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.008     Document Type: Review

References (49)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
2. Well-Olivier C., Van der Linden M., Schutter I., Dagan R., Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era. A European perspective. BMC Infect Dis 2012, 12:207.
3. World Health Organization Pneumococcal vaccines. WHO Position Paper. Wkly Epidemiol Rec 2012, 87:129-144.
4. Muñoz-Almagro C., Ciruela P., Esteva C., Marco F., Navarro M., Bartolome R., et al. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in catalonia, Spain. J Infect 2011, 63:151-162.
5. Myint T.T., Madhava H., Balmer P., Christopoulou D., Attal S., Menegas D., et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013, 30:127-151.
6. Grijalva C.G., Pelton S.I. A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Curr Opin Pediatr 2011, 23:98-104.
7. Cohen R., Levy C., de La Rocque F., Gelbert N., Wollner A., Fritzell B., et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006, 25:1001-1007.
8. Weinberger D.M., Malley R., Lipstich M. Serotype replacement after pneumococcal vaccination. Lancet 2011, 378:1962-1973.
9. Song J.H., Dagan R., Klugman K.P., Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 2012, 30:2728-2737.
10. Jefferies J.M., Macdonald E., Faust S.N., Clarke S.C. 13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccine 2011, 7:1012-1018.
11. Center for Disease Control and Prevention. Invasive Pneumococcal Disease in Young Children Before Licensure of 13-Valent Pneumococcal Conjugate Vaccine-United States, 2007. MMWR Morb Mortal Wkly Rep 2010, 59:253-257.
12. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:9127-9131.
13. Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
14. Critical Appraisal Skills Programme Appraisal Tools [Internet] 2013, Oxford, UK. Available from: http://www.casp-uk.net/. [cited 15.03.13].
15. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996, 17:1-12.
16. Higgins J.P., Thompson S.G. Quantifying heterogeneity in meta-analysis. Stat Med 2002, 21:1539-1558.
17. Frenck R.W., Gurtman A., Rubino J., Smith W., van Cleeff M., Jayawardene D., et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012, 19:1296-1303.
18. Gimenez-Sanchez F., Kieninger D.M., Kueper K., Martinón-Torres F., Bernaola E., Diez-Domingo J., et al. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:6042-6048.
19. Martinón-Torres F., Gimenez-Sanchez F., Gurtman A., Bernaola E., Diez-Domingo J., Carmona A., et al. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Pediatr Infect Dis J 2012, 31:392-399.
20. Vanderkooi O.G., Scheifele D.W., Girgenti D., Halperin S.A., Patterson S.D., Gruber W.C., et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 2012, 31:72-77.
21. Kim D.S., Shin S.H., Lee H.J., Hong Y.J., Lee S.Y., Choi K.M., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines. Pediatr Infect Dis J 2013, 32:266-273.
22. Singleton R., Wenger J., Klejka J.A., Bulkow L.R., Thompson A., Sarkozy D., et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in alaska native children: results of a clinical trial. Pediatr Infect Dis J 2013, 32:257-263.
23. Amdekar Y.K., Lalwani S.K., Bavdekar A., Balasubramanian S., Chhatwal J., Bhat S.R., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India. Pediatr Infect Dis J 2013, 32:509-516.
24. Weckx L.Y., Thompson A., Berezin E.N., de Faria S.M., da Cunha C.A., Pride M., et al. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine 2012, 30:7566-7572.
25. Huang L.M., Lin T.Y., Juergens C. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. Vaccine 2012, 30:2054-2059.
26. Grimprel E., Laudat F., Patterson S., Baker S.A., Sidhu M.S., Gruber W.C., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine 2011, 29:9675-9683.
27. Bryant K.A., Block S.L., Baker S.A., Gruber W.C., Scott D.A. PCV13 infant study group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010, 25:866-875.
28. Esposito S., Tansey S., Thompson A., Razmpour A., Liang J., Jones T.R., et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010, 17:1017-1026.
29. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28:4192-4203.
30. Snape M.D., Klinger C.L., Daniels E.D., John T.M., Layton H., Rollinson L., et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J 2010, 29:e80-e90.
31. Yeh S.H., Gurtman A., Hurley D.C., Block S.L., Schwartz R.H., Patterson S., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126:e493-e505.
32. Lucero M.G., Dulalia V.E., Nillos L.T., Williams G., Parreño R.A., Nohynek H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009, 4. CD004977.
33. Hausdorff W.P., Hoet B., Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?. BMC Pediatr 2010, 10:4.
34. Oosterhuis-Kafeja F., Beutels P., Van Damme P. Immunogenicity, efficay, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007, 25:2194-2212.
35. Pavia M., Bianco A., Nobile C.G., Marinelli P., Angelillo I.F. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009, 123:e1103-e1110.
36. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365:1139-1146.
37. Taylor S., Marchisio P., Vergison A., Harriague J., Hausdorff W.P., Haggard M. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012, 54:1765-1773.
38. Stamboulidis K., Chatzaki D., Poulakou G., Ioannidou S., Lebessi E., Katsarolis I., et al. The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J 2011, 30:551-555.
39. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsène J.P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(4 Suppl.):S66-S76.
40. Scott P., Rutjes A.W., Bermetz L., Robert N., Scott S., Lourenço T., et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 2011, 29:9711-9721.
41. Rückinger S., Dagan R., Albers L., Schönberger K., von Kries R. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine 2011, 29:9600-9606.
42. Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults. Drugs 2012, 72:1243-1255.
43. Paradiso P.R. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 2011, 52:1241-1247.
44. Adam D., Fehnle K. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Vaccine 2008, 26:5944-5951.
45. Crum-Cianflone N.F., Huppler Hullsiek K., Roediger M., Ganesan A., Patel S., Landrum M.L., et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010, 202:1114-1125.
46. CDC Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2012, 61:816-819.
47. Laferriere C. The immunogenicity of pneumococcal polysaccharides in infants and children: a meta-regression. Vaccine 2011, 29:6838-6847.
48. Frenck R.W., Yeh S. The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. Expert Opin Biol Ther 2012, 12:63-77.
49. Schwarz T.F., Flamaing J., Rümke H.C., Penzes J., Juergens C., Wenz A., et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011, 29:5195-5202.